RA-9

CAS No. 919091-63-7

RA-9( —— )

Catalog No. M22045 CAS No. 919091-63-7

RA-9 is a potent and selective proteasome-associated inhibitor of deubiquitinating enzymes (DUBs), with favorable toxicity profile and anticancer activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 41 Get Quote
10MG 68 Get Quote
25MG 120 Get Quote
50MG 177 Get Quote
100MG 277 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    RA-9
  • Note
    Research use only, not for human use.
  • Brief Description
    RA-9 is a potent and selective proteasome-associated inhibitor of deubiquitinating enzymes (DUBs), with favorable toxicity profile and anticancer activity.
  • Description
    RA-9 is a potent and selective proteasome-associated inhibitor of deubiquitinating enzymes (DUBs), with favorable toxicity profile and anticancer activity. RA-9 selectively induces apoptosis in ovarian cancer cell lines.The characterization of RA-9 as a small-molecule inhibitor of proteasome-associated DUBs.?Treatment with RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors.?Loss of cell viability following RA-9 exposure is associated with an unfolded protein response as mechanism to compensate for unsustainable levels of proteotoxic stress.?In vivo treatment with RA-9 retards tumor growth, increases overall survival, and was well tolerated by the host.
  • In Vitro
    Cell Viability Assay Cell Line:Cisplatin-sensitive ovarian cancer cell lines TOV-21G and ES-2, Cisplatin-resistant ovarian cancer cell lines HEY and OVCAR-3, primary ovarian cancer cellsConcentration:10, 20, 30 μM Incubation Time:48 hours Result:Compromised the viability of ovarian cancer cells in a dose-dependent fashion.Cell Cycle Analysis Cell Line:ES-2 cells Concentration:1.25, 5 μM Incubation Time:18 hours Result:Resulted in a dose-dependent increase in the fraction of ES-2 cells in the G2-M cell cycle phase.Western Blot Analysis Cell Line:ES-2, SKOV-3 and TOV-21G ovarian cancer cells Concentration:5 μM Incubation Time:0-24 h Result:Caused a time-dependent increase in the steady levels of the early ER-stress marker GRP-78, as well as the late ER-stress markers IRE1-α and Ero1L-α.
  • In Vivo
    Animal Model:Six-week-old female immunodeficient (NCr nu/nu) mice Dosage:5 mg/kg Administration:I.p; one-day on, two-days off Result:Significant reduction in tumor burden at day 12.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis|deubiquitinating enzymes (DUBs)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    919091-63-7
  • Formula Weight
    365.34
  • Molecular Formula
    C19H15N3O5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:4 mg/mL (10.95 mM; ultrasonic and warming and heat to 80°C)
  • SMILES
    [O-][N+](=O)c1ccc(\C=C2/CNC\C(=C/c3ccc(cc3)[N+]([O-])=O)C2=O)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Coughlin K , Anchoori R , Iizuka Y , et al. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20(12):3174-86.
molnova catalog
related products
  • KT5823

    KT5823 is a selective and potent cGMP-dependent protein kinase (PKG) inhibitor with inhibitory effects on PKA and PKC.KT5823 increases thyroid-stimulating hormone-induced (Na+/I- symporter) NIS expression and iodide ion uptake by modulating sodium iodide symporter protein expression and activity in thyroid cells. KT5823 induces apoptosis.

  • Urolithin C

    Urolithin C is a gut metabolite of ellagic acid. Urolithin C induces apoptosis in PC12 cells through a mitochondria-mediated pathway.

  • AAPK-25

    AAPK-25, a potent and selective dual inhibitor of Aurora/PLK, causes mitotic delay and cell arrest in prometaphase, via phosphorylation of the biomarker histone H3Ser10, followed by a surge in apoptosis.